Evaluation of CardioprOtection by the use of betablocker Nebivolol in paTients with bReast cancer Or diffuse Large B cell lymphoma undergoing chemotherapy with anthracyclines: a randomized controlled trial. - Evaluation of CardioprOtection by the use of betablocker Nebivolol in paTients with bReast cancer Or

IRCCS ISTITUTO CLINICO HUMANITAS0 个研究点目标入组 80 人开始时间: 2018年9月14日最近更新: 2018年9月24日

适应症

试验速览

暂无简介。

•1.Age =18 years
•2.Established histological diagnosis of BC or DLBCL
•3.Planned first-line chemotherapy with anthracyclines
•4.LVEF =55% (assessed by echocardiography)
•5.Ability to provide informed consent
•6.For women of childbearing potential a negative serum pregnancy is required before the inclusion in the study
•Are the trial subjects under 18? no
•Number of subjects for this age range: 1
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 50
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 30

•1.Known intolerance/contraindications to betablocker therapy
•2.Known hypersensitivity to nebivolol or any of the excipients
•3.History of coronary artery disease
•4.History of cardiomyopathy
•5.History of heart failure
•6.Ongoing treatment with betablockers for other indications
•7.Heart rate <60 beats per minute
•8.Arterial blood pressure <100/60 mmHg
•9.Contraindications to undergo MRI (e.g., non compatible pacemakers or metallic prosthesis)
•10.Pregnancy or lactation
•11.Currently participating in another trial

发起方

IRCCS ISTITUTO CLINICO HUMANITAS